HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat is a non-selective HDAC inhibitor which targets class 1 and class 2 HDACs and is used in the treatment of cutaneous T cell lymphoma (CTCL) [131].